Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine

References

• Garg A, Singh S, Rao VU, et al. Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. Drug Dev Ind Pharm. 2009;35:455–470.
   PubMed Web of Science ®Google Scholar
• Isaac J, Ganguly S, Ghosh A. Co-milling of telmisartan with poly(vinyl alcohol) – an alkalinizer free green approach to ensure its bioavailability. Eur J Pharm Biopharm. 2016;101:43–52.
   PubMed Web of Science ®Google Scholar
• Loh ZH, Samanta AK, Sia Heng PW. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10:255–274.
   Web of Science ®Google Scholar
• Niwa T, Yoshida M, Hayashi N, et al. One step preparation of spherical drug particles by contamination-free dry milling technique with corn starch beads. Int J Pharm. 2017;528:624–636.
   PubMedGoogle Scholar
• Lim RTY, Ng WK, Tan RBH. Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing. Powder Technol. 2013;240:79–87.
   Web of Science ®Google Scholar
• Kürti L, Kukovecz Á, Kozma G, et al. Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles. Powder Technol. 2011;212:210–217.
   Web of Science ®Google Scholar
• Li J, Yang Y, Zhao M, et al. Improved oral bioavailability of probucol by dry media-milling. Mater Sci Eng C. 2017;78:780–786.
   PubMed Web of Science ®Google Scholar
• Karashima M, Sano N, Yamamoto S, et al. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations. Eur J Pharm Biopharm. 2017;115:65–72.
   PubMed Web of Science ®Google Scholar
• Colombo G, Bortolotti F, Chiapponi V, et al. Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. Int J Pharm. 2016;514:229–237.
   PubMed Web of Science ®Google Scholar
• Scherliesz R, Mönckedieck M, Young K, et al. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice. Int J Pharm. 2015;479:408–415.
   PubMedGoogle Scholar
• Trows S, Scherliesz R. Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug. Powder Technol. 2016;292:223–231.
   Web of Science ®Google Scholar
• Parumasivam T, Chang RYK, Abdelghany S, et al. Dry powder inhalable formulations for anti-tubercular therapy. Adv Drug Deliv Rev. 2016;102:83–101.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146–157.
   PubMed Web of Science ®Google Scholar
• Warnken ZN, Smyth HDC, Watts AB, et al. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol. 2016;35:213–222.
   Web of Science ®Google Scholar
• Horvát S, Fehér A, Wolburg H, et al. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm. 2009;72:252–259.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Furubayashi T, Tomisaki M, et al. Nasal drug absorption from powder formulations: the effect of three types of hydroxypropyl cellulose (HPC). Eur J Pharm Sci. 2017;96:284–289.
   PubMed Web of Science ®Google Scholar
• Gavini E, Hegge AB, Rassu G, et al. Nasal administration of Carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm. 2006;307:9–15.
   PubMed Web of Science ®Google Scholar
• Callens C, Ceulemans J, Ludwig A, et al. Rheological study on mucoadhesivity of some nasal powder formulations. Eur J Pharm Biopharm. 2003;55:323–328.
   PubMed Web of Science ®Google Scholar
• Kublik H, Vidgren M. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev. 1998;29:157–177.
   PubMed Web of Science ®Google Scholar
• Bartos C, Ambrus R, Sipos P, et al. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. Int J Pharm. 2015;491:198–207.
   PubMedGoogle Scholar
• Brough C, Miller DA, Keen J, et al. Use of polyvinyl alcohol as a solubility-enhancing polymer for poorly water soluble drug delivery. Part 1. AAPS PharmSciTech. 2016;17:167–179.
   PubMedGoogle Scholar
• Kürti L, Gáspár R, Márki Á, et al. In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. Eur J Pharm Sci. 2013;50:86–92.
   PubMed Web of Science ®Google Scholar
• Hales D, Vlase L, Porav SA, et al. A quality by design (QbD) study on enoxaparin sodium loaded polymeric microspheres for colon-specific delivery. Eur J Pharm Sci. 2017;100:249–261.
   PubMed Web of Science ®Google Scholar
• Karimi K, Pallagi E, Szabo-Revesz P, et al. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach. DDDT. 2016;10:3331–3343.
   PubMed Web of Science ®Google Scholar
• Pallagi E, Ambrus R, Szabó-Révész P, et al. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. Int J Pharm. 2015;491:384–392.
   PubMed Web of Science ®Google Scholar
• Riley BS, Li X. Quality by design and process analytical technology for sterile products—where are we now? AAPS PharmSciTech. 2011;12:114–118.
   PubMed Web of Science ®Google Scholar
• Gavan A, Porfire A, Marina C, et al. Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach. Acta Pharm. 2017;67:53–70.
   PubMed Web of Science ®Google Scholar
• Porfire A, Muntean DM, Rus L, et al. A quality by design approach for the development of lyophilized liposomes with simvastatin. Saudi Pharm J. 2017;25(7):981–992.
   PubMed Web of Science ®Google Scholar
• Iurian S, Turdean L, Tomuta I. Risk assessment and experimental design in the development of a prolonged release drug delivery system with paliperidone. DDDT. 2017;11:733–746.
   PubMed Web of Science ®Google Scholar
• Iurian S, Tomuta I, Bogdan C, et al. Defining the design space for freeze-dried orodispersible tablets with meloxicam. Drug Dev Ind Pharm. 2016;42:1977–1989.
   PubMed Web of Science ®Google Scholar
• Casian T, Iurian S, Bogdan C, et al. QbD for pediatric oral lyophilisates development: risk assessment followed by screening and optimization. Drug Dev Ind Pharm. 2017;43(12):1932–1944.
   PubMed Web of Science ®Google Scholar
• Gieszinger P, Csóka I, Pallagi E, et al. Preliminary study of nanonized lamotrigine containing products for nasal powder formulation. DDDT. 2017;11:2453–2466.
   PubMed Web of Science ®Google Scholar
• Garg N, Sharma G, Singh B, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an improved dermatokinetic profile for inflammatory disorder(s). Int J Pharm. 2017;517:413–431.
   PubMed Web of Science ®Google Scholar
• Pallagi E, Paál T, Csóka I. Presentation of the Quality by Design concept and its application possibilities in the pharmaceutical technological development of nano-systems. Gyógyszerészet. 2015;59:387–395.
   Google Scholar
• Bastogne T. Quality-by-design of nanopharmaceuticals – a state of the art. Nanomed Nanotechnol. 2017;13:2151–2157.
   PubMed Web of Science ®Google Scholar